Who
Frederick W. Driscoll
Director
Company insider
Files Form 4 as: Director, Cellectar Biosciences; Director, Lite Strategy; Director, Cue Biopharma; Chief Financial Officer, Renovacor; Chief Financial Officer, Flexion Therapeutics; Director, ImmunityBio; Director, Oxigene; VP, CFO & Treasurer, Novavax.
In numbers
- Trades disclosed
- 82
- Buys
- 6
- Sells
- 4
- Bought
- $201K
- Sold
- $1.5M
- Companies
- 9
- Companies where not an officer
- 5
- First trade
- 16 Nov 2007
- Last trade
- 7 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 14 Nov 2025filed 18 Nov 2025 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 | filing |
| 15 Jul 2025filed 17 Jul 2025 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 29 Sep 2023filed 12 Oct 2023 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 28 Jun 2023filed 28 Jun 2023 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jul 2022filed 7 Jul 2022 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —87.5 at $0.00 | filing |
| 24 Jun 2022filed 1 Aug 2022 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 28 Mar 2022filed 28 Mar 2022 | Renovacoroption or derivative | SEC FORM 4 Code A | —155,325 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code D | —168,000 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeutics | SEC FORM 4 Code D | $261K30,680 at $8.50 | filing |
| 3 Sep 2021filed 7 Sep 2021 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $20K19,417 at $1.04 | filing |
| 1 Jul 2021filed 6 Jul 2021 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 30 Jun 2021filed 2 Jul 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,000 at $0.00 | filing |
News
ImmunityBio (NASDAQ:IBRX) Shares Down 6.4% – Here's WhyIBRX · dailypolitical.com · 19 Oct 2026Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström PatientsCLRB · rttnews.com · 15 Oct 2026Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry ArchiveLITS · manilatimes.net · 13 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)NVAX · themarketsdaily.com · 11 Oct 2026Novavax (NASDAQ:NVAX) Sees Large Volume Increase – Should You Buy?NVAX · dailypolitical.com · 9 Oct 2026ImmunityBio (NASDAQ:IBRX) Director Cheryl Cohen Sells 81,056 Shares of StockIBRX · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Frederick W. Driscoll; 6 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.